Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Key Inclusion Criteria: * Diagnosis of B-cell indolent non-Hodgkin lymphoma (iNHL),diffuse large B-cell lymphoma (DLBCL),mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) as documented by medical records and with histology based on criteria established by the World Health Organization * For institutions that have Phase 3 or Phase 4 protocols studying idelalisib (Zydelig®; GS-1101); individuals with malignancies being studied in these protocols must have failed screening and be registered as a screen failure in the respective idelalisib protocol * Prior treatment for lymphoid malignancy * Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy * Discontinuation of all therapy for the treatment of cancer ≥ 3 weeks before the start of study drug * All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before the start of study drug * Karnofsky performance status of ≥ 60 * Life expectancy of at least 3 months Key Exclusion Criteria: * Known histological transformation from iNHL or CLL to an aggressive form of NHL (ie, Richter transformation) * Known active central nervous system or leptomeningeal lymphoma * Presence of known intermediate- or high-grade myelodysplastic syndrome * Current therapy with agents that reduce gastric acidity, including but not limited to antacids, H2 inhibitors, and proton pump inhibitors * Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of …